Publications

November 2008
Case

Adnexus Therapeutics, Inc.: Considering the Exit

By: Vicki L. Sato and Rachel Gordon

Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry

Article

Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.

By: Ariel Dora Stern

The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and... View Details

Keywords: Biomarkers; Information Management; Health Care and Treatment; Motivation and Incentives

Find at Harvard

Read Now

07 Jun 2023
News

Martine Rothblatt: Making Implausible Dreams Reality

November 2022 (Revised April 2024)
Case

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia

Article

What Evolution Can Teach Us About Innovation

By: Noubar Afeyan and Gary P. Pisano

Many people believe that the process for achieving breakthrough innovations is chaotic, random, and unmanageable. But that view is flawed, the authors argue. Breakthroughs can be systematically generated using a process modeled on the principles that drive evolution in... View Details

Keywords: Breakthrough Innovation; Variance Generation; Selection Pressure; Emergent Discovery; Innovation and Invention; Value Creation; Innovation Leadership

Find at Harvard

Register to Read

February 2010
Background Note

Millipore Background Note

By: Elie Ofek and Natalie Kindred

This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details

Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Biotechnology Industry; Pharmaceutical Industry

Find at Harvard

February 2016 (Revised September 2017)
Case

Neurotrack and the Alzheimer's Puzzle

By: Richard G. Hamermesh, Liz Kind and Carin-Isabel Knoop

Elli Kaplan founded Neurotrack in 2012 with a breakthrough noninvasive cognitive diagnostics test that will detect Alzheimer's disease in its earliest pre-symptomatic stages. While the company has gained great traction in the three years since it was started, with no... View Details

Keywords: Alzheimer's Disease; Diagnostics; Healthcare; Entrepreneurship; Health Disorders; Science-Based Business; Business Model; Medical Devices and Supplies Industry; United States

August 2024 (Revised August 2024)
Background Note

Note on Adherence in Healthcare

By: Regina E. Herzlinger, Zachery Page and Ben Creo

This note provides an overview of adherence in healthcare. It discusses systemwide costs of non-adherence, common barriers to adherence, relevant stakeholders, novel compliance tactics, and the impact on digital therapeutic adoption. It is recommended as a companion to... View Details

Keywords: Health Care and Treatment; Behavior; Health Industry

04 Apr 2016
HBS Seminar

Ariel Stern, Harvard Business School

September 2013
Article

Testimonials Do Not Convert Patients from Brand to Generic Medication

By: John Beshears, James J. Choi, David Laibson, Brigitte C. Madrian and Gwendolyn Reynolds

Objectives: To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand name prescription medications to lower-cost therapeutic equivalents, and whether the testimonial's efficacy increases when... View Details

Keywords: Testimonial; Peer Information; Social Proximity; Communication; Generic Medication; Familiarity; Marketing Communications; Decision Choices and Conditions; Identity; Health Care and Treatment; Marketing Reference Programs; Power and Influence; Brands and Branding; Health Industry

Read Now

October 2012 (Revised March 2022)
Case

Kleiner-Perkins and Genentech: When Venture Capital Met Science

By: Felda Hardymon and Tom Nicholas

Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into... View Details

Keywords: Innovation ＆ Entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Information Technology; Science; Biotechnology Industry; United States

April 2019
Case

Barber Cardiosystems

By: Ranjay Gulati and Paul S. Myers

Barber Cardiosystems, based in Melbourne, Australia, designs and manufactures therapeutic devices used for treatment of coronary conditions. Over four decades, it has grown to be among the top 200 medical device companies in the world. It competes against much larger... View Details

Keywords: Organizational Behavior; Strategic Alignment; Cost Management; Performance Productivity; Organizational Culture; Motivation and Incentives; Organizational Design; Strategy; Leadership; Medical Devices and Supplies Industry; Australia

May 2005 (Revised April 2010)
Case

GlaxoSmithKline: Reorganizing Drug Discovery (A)

By: Robert S. Huckman and Eli Strick

Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry

November 2024
Teaching Note

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Medical Devices and Supplies Industry; United States; District of Columbia